Fever News and Research

RSS

University of Maryland receives renewed NIH funding for vaccine research

The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has successfully competed for and received a renewed contract to conduct basic research and clinical studies of vaccines, diagnostics, and therapeutics. Support for this work to combat existing and emerging infectious diseases is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

27 Sep 2013

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.

26 Sep 2013

First global analysis of Kawasaki disease published by PLOS ONE

After more than four decades of research, strong evidence now shows that Kawasaki disease has a distinct seasonal occurrence shared by regions across the Northern hemisphere.

24 Sep 2013

ACR journals publish guide that provides new treatments for children with systemic JIA

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative.

24 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

New blood test accurately differentiates viral and bacterial infections

A blood test developed by researchers at Duke Medicine showed more than 90-percent accuracy in distinguishing between viral and bacterial infections when tested in people with respiratory illnesses.

19 Sep 2013

Inhaled corticosteroid increases risk for pneumonia reoccurrence

A University of Alberta researcher says health professionals should be cautious about prescribing inhaled corticosteroids to high-risk patients such as pneumonia survivors, citing a twofold risk for repeat infection.

19 Sep 2013

New series of lectures focus on rodents, medicines and drug developments

Rodents, medicines and drug developments are all on the agenda during a new series of public lectures being staged by the University of Greenwich's Faculty of Engineering & Science.

18 Sep 2013

Biocryst Wins Potentially $22M NIAID Contract To Develop Marburg Virus Disease Drug

...

17 Sep 2013

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.

17 Sep 2013

Tips for parents of children with cancer

September is Childhood Cancer Awareness Month, and Lisa Diller, MD, chief medical officer of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, advises parents to remain positive if their child is among the 12,000 children in the United States diagnosed with cancer each year.

13 Sep 2013

Scottsdale Healthcare, TGen initiate Thunder God vine clinical trial in pancreatic cancer patients

Taking a page from Chinese herbal medicine, Scottsdale Healthcare and the Translational Genomics Research Institute today initiated the first-in-human clinical trial for pancreatic cancer patients using a compound derived from a plant known as "Thunder God vine."

13 Sep 2013

Proper precautions may help people with allergies enjoy the beautiful fall weather

As summer comes to a close, kids head back to school and preparation for fall begins, don't' forget to consider fall allergies. An estimated 35 million Americans suffer from allergies, which in the fall begin in late August and peak in September. For those with fall allergies, three triggers typically occur - ragweed, indoor allergens and infections.

12 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Early respiratory infections linked to Type 1 diabetes

Researchers from Germany have found that respiratory infections in early life are linked to islet autoimmunity, implicating them as a potential risk factor in the development of Type 1 diabetes.

9 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Sanofi Pasteur, the vaccines division of Sanofi, today announced topline results of a large-scale, multi-center efficacy trial in people 65 years of age and older showing a superior clinical benefit of Fluzone High-Dose (Influenza Virus Vaccine) relative to the standard dose of Fluzone vaccine in preventing influenza.

26 Aug 2013

HEALTHY FUTURES project aims to address risk of outbreaks, transmission of VBDs

Important outputs are starting to arise from the HEALTHY FUTURES (Health, environmental change and adaptive capacity) project, which aims to address the risk of outbreaks and transmission of three water-related vector-borne diseases (VBDs) in eastern Africa. HEALTHY FUTURES is now past its halfway point, with less than eighteen months of the project remaining.